Related Experiment Video
Updated: May 28, 2026
07:51
Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal
Argyris Tzouvelekis1, George Koliakos, Paschalis Ntolios
1Department of Pneumonology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Journal of Translational Medicine
|October 25, 2011
Summary
Adipose-derived stem cells (ADSCs) show promise for treating idiopathic pulmonary fibrosis (IPF). This Phase Ib trial found ADSC-SVF infusion to be safe and well-tolerated, with potential functional improvements in IPF patients.
Area of Science:
- Regenerative Medicine
- Pulmonology
- Stem Cell Therapy
Background:
- Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease with limited treatment options.
- The exact causes of IPF remain unclear, hindering effective therapeutic development.
Purpose of the Study:
- To evaluate the safety and tolerability of adipose-derived stem cells (ADSCs) stromal vascular fraction (SVF) in patients with IPF.
- To propose a Phase Ib clinical trial protocol for ADSC-SVF therapy in IPF.
Main Methods:
- A prospective, unicentric, non-randomized Phase Ib clinical trial was designed.
- Eligible IPF patients underwent lipoaspiration for ADSC-SVF isolation.
- ADSC-SVF was administered via endobronchial infusion to the lower lobes, repeated thrice at monthly intervals.
Main Results:
- Preliminary data indicated no significant adverse events, including allergic reactions, infections, or disease exacerbations.
- Six-month follow-up showed marginal improvements in 6-minute walking distance and forced vital capacity.
Conclusions:
- Adipose tissue is a safe and accessible source for stem cells for IPF treatment.
- Pilot safety studies are crucial for establishing a foundation for larger clinical trials.
- Further large-scale, placebo-controlled trials are necessary to confirm the efficacy of ADSC-SVF in IPF.
